China Latanoprost Market Investigation Report 2015-2019
DUBLIN, Aug. 28, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/lcc936/investigation) has announced the addition of the "Investigation Report on China's Latanoprost Market, 2010-2019" report to their offering.
Developed by Pharmacia & Upjohn in 1995, latanoprost is a selective prostaglandin receptor agonist which effectively reduces intraocular pressure. As the first pressure- lowering prostaglandin approved by FDA, latanoprost (under the trade name of Xalatan) entered China in 1999. In 2004, latanoprost eye drop developed by Lunan Better Pharmaceutical Co., Ltd was approved to be marketed, followed by products of Merro Pharmaceutical Co., Ltd, Hengrui Pharmaceutical and China Resources Zizhu Pharmaceutical Co., Ltd. Latanoprost has already become the first- line drug for the treatment of glaucoma.
Latanoprost developed fast after entering China, with sales value rising from CNY 25.27 million in 2013 to CNY 26.40 million in 2014 with a year-on-year growth of 4.47% and CAGR during the period of 2010- 2014 reaching 24.02%. With ageing population, the incidence of glaucoma continues to increase. Unlike cataract which can be treated with surgery, glaucoma provides a large market for conservative and postoperative medication. Therefore, latanoprost enjoys a vast demand in China.
Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn (Belgium), Lunan Better Pharmaceutical Co., Ltd, China Resources Zizhu Pharmaceutical Co., Ltd and Pharmacia & Upjohn (Sweden) occupy the majority of the market share, among which Pfizer Manufacturing Belgium NV had the largest market share of about 43.1% for sales value in 2014. However, its market share was even larger i.e. 44.3% in 2013. Meanwhile, the market share of Pharmacia & Upjohn also decreased from 30.8% in 2013 to 29.5% in 2014. On the contrary, local manufacturers like Lunan Better Pharmaceutical Co., Ltd and China Resources Zizhu Pharmaceutical Co., Ltd both reported an increased market share (a 1.5% increase from 13.7% to 15.2% achieved by Lunan Better) in 2014 and will gain a larger share as biological technology develops further and they come to know more about domestic drugs.
Key Topics Covered:
1 Related Concepts of Latanoprost
2 Market Profile of Latanoprost in China
3 Survey on Sales Status of Latanoprost in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Latanoprost in China, 2010-2014
5 Survey on Dosage Forms of Latanoprost in China, 2010-2014
6 Reference Price of Latanoprost in Chinese Hospitals in 2014
7 Major Manufacturers of Latanoprost in Chinese Market, 2010-2014
8 Market Outlook of Latanoprost in China, 2015-2019
Companies Mentioned
- China Resources Zizhu Pharmaceutical Co., Ltd
- Lunan Better Pharmaceutical Co., Ltd
- Pfizer Manufacturing Belgium NV
- Pharmacia & Upjohn (Belgium)
For more information visit http://www.researchandmarkets.com/research/lcc936/investigation
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article